IceCure Medical has issued bonds worth US$5.7 million
IceCure Medical Ltd. has completed a fundraising to refinance and develop the company.
IceCure is an Israeli medical device company that has developed technology to eliminate benign and cancerous tumors in the breast and other parts of the body by freezing the tumor during treatment in a clinic and without surgery, using the ProSense system developed at the Elisha Private Hospital in Haifa.
Oaklins’ team in Israel advised IceCure Medical Ltd. and acted as the leader of the distributors’ consortium.
Talk to the deal team
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn more